



## PRESS RELEASE

### PAION ANNUAL GENERAL MEETING AND CENES ACQUISITION UPDATE

Aachen, 6 May 2008 - The biopharmaceutical company PAION AG (FSE PA8, ISIN DE000A0B65S3), today announced that during their Annual General Meeting held yesterday, the resolutions proposed by the management board and supervisory board were adopted with large majorities. The results are available at the company's website [www.paion.de/hv](http://www.paion.de/hv).

In addition, PAION notes that the Scheme Document which sets out, amongst other things, the full terms and conditions of the proposed acquisition of CeNeS Pharmaceuticals plc has been posted to CeNeS' shareholders and will be available shortly at [www.paion.de/investors](http://www.paion.de/investors).

###

#### **About PAION**

PAION is a biopharmaceutical company specializing in developing and commercializing innovative drugs for the treatment of thrombotic diseases, that is, diseases caused by the obstruction of a blood vessel by a blood clot. Currently, PAION's focus is on the causal treatment of acute ischemic stroke. PAION intends to build and expand its portfolio of drug candidates using a "search-and-development" approach. Accordingly, PAION seeks to identify promising new compounds, license or otherwise acquire them and advance them through the clinical development and regulatory approval process. Where appropriate, particularly during the late stages of the clinical development and approval process and the commercialization phase, PAION seeks to collaborate with experienced partners.

#### **Disclaimer**

On April 10, 2008, PAION announced a recommended offer for the entire issued and to be issued share capital of CeNeS Pharmaceuticals plc. Therefore the Company is currently in an offer period as defined by the Takeover Code of the UK Panel on Takeovers and Mergers. Because of this, shareholders need to be aware of certain additional reporting requirements regarding transactions in PAION shares. For further information, please see the full text of the acquisition announcement published on April 10, 2008, and the press release explaining the additional reporting requirements published on April 14, 2008, both of which are available on PAION's website at [www.paion.de/investors](http://www.paion.de/investors).

This communication is neither an offer to buy securities nor a solicitation for an offer to sell securities. Securities may not be offered or sold in the United

States absent registration or an exemption from registration. There will be no public offer of the shares of PAION AG in the United States.

**Contact**

Dr. Peer Nils Schroeder, Investor Relations / Public Relations

PAION AG

Martinstrasse 10-12

52062 Aachen – Germany

Tel. +49 241 4453-152

E-mail [pn.schroeder@paion.de](mailto:pn.schroeder@paion.de)

[www.paion.de](http://www.paion.de)